Clearmind Medicine

About

Funding history · 5 rounds · — total

Headcount over time

Q&A

What is Clearmind Medicine's primary focus?

Clearmind Medicine Inc. is a clinical-stage pharmaceutical biotechnology company focused on the discovery and development of novel psychedelic-derived therapeutics for widespread and underserved health problems, including alcohol use disorder, binge eating, depression, anxiety disorders, post-traumatic stress disorder, and treatment-resistant depression.

Where are Clearmind Medicine's R&D activities conducted?

While headquartered in Vancouver, Canada, Clearmind Medicine's R&D activities are conducted in Israel, and it has an office in Tel Aviv.

What is the company's employee count?

Clearmind Medicine has 1-10 employees.

When did Clearmind Medicine become a public company?

Clearmind Medicine went public on the CSE in June 2022 and on NASDAQ in November 2022.

What was the amount raised in Clearmind Medicine's Public Offering in November 2022?

In November 2022, Clearmind Medicine raised $7,500,005.5 in a Public Offering.

What was the amount raised in Clearmind Medicine's Public Offering in April 2023?

In April 2023, Clearmind Medicine raised $3,514,460 in a Public Offering.

What was the amount raised in Clearmind Medicine's Public Offering in September 2023?

In September 2023, Clearmind Medicine raised $2,250,000 in a Public Offering.

What was the amount raised in Clearmind Medicine's Public Offering in January 2024?

In January 2024, Clearmind Medicine raised $2,400,000 in a Public Offering.

What was the amount of Clearmind Medicine's Convertible Debt round in September 2025?

In September 2025, Clearmind Medicine secured $10,000,000 in a Convertible Debt round.

What is the company's market capitalization?

Clearmind Medicine has a market capitalization of $5,298,975.

Sectors & technology

Highlights

Tags